Release date: 2024-11-12 15:04:44 Article From: Lucius Laos Recommended: 131
Retinitis due to cytomegalovirus is indeed a serious eye infection that mainly affects people with weakened immune systems, such as AIDS patients. The virus can continue to damage the retina, leading to vision problems such as vision loss, reduced visual field and blurred vision, and can even cause irreversible vision loss if left untreated. Valcyte (trade name: Wansavi) plays an important role in clinical practice as an effective antiviral drug for this condition.
Cytomegalovirus (CMV) is a herpes virus that generally does not cause disease in immunocompetent individuals, but in immunocompromised individuals, it can cause gastrointestinal tract, central nervous system, lung disease, and retinitis. Among them, retinitis is one of the most common diseases, with retinitis occurring in about 15% of patients with intrauterine infection. Symptoms of CMV retinitis may include blurred vision, dark shadows in front of the eyes, eye pain, redness, and vitreous opacity, which may indicate an eye infection or inflammation.
Valcyte is an antiviral drug mainly used to treat retinitis due to cytomegalovirus in AIDS patients. In addition, it is used to prevent CMV disease that may occur in high-risk adults after combined kidney, heart, and pancreatic transplantation, and in children after kidney and heart transplantation. This medicine works in the following ways:
Valcyte is a derivative of ganciclovir and is rapidly converted to ganciclovir in the digestive system after oral administration. This transformation process increases the bioavailability of the drug and reduces the potential toxicity.
Valcyte effectively inhibits cytomegalovirus replication by blocking viral DNA synthesis. This helps to reduce the patient's symptoms and prevents the virus from further damaging the retina.
Valcyte has been widely used in clinical practice and has achieved remarkable therapeutic effects. For people with weakened immune systems, such as AIDS patients, this drug becomes an important option for the treatment of cytomegalovirus retinitis. Through the rational use of Valcyte, the progression of the disease can be effectively controlled and serious complications such as vision loss can be prevented.
When using Valcyte (vansavil), the following should be noted:
The medication should be strictly taken according to the doctor's instructions, and the dose should not be adjusted or discontinued by yourself. The doctor will develop a personalized medication plan based on the patient's specific situation.
There may be some adverse reactions with the use of Valcyte, such as gastrointestinal reactions such as diarrhea, nausea, vomiting, abdominal pain, and hematologic reactions such as neutropenia, anemia, etc. Patients should be monitored regularly and seek medical attention in case of serious adverse reactions.
It is forbidden for those who are allergic to Valcyte; Special populations such as pregnant women, lactating women, and people with renal insufficiency should be used with caution or contraindicated. Before use, patients should inform their doctor of their allergies, medications, and current medical condition.
Valcyte plays an important role as an effective antiviral drug in the treatment of retinitis caused by cytomegalovirus. With the rational use of this drug, it is possible to control the progression of the disease and prevent the occurrence of serious complications such as vision loss.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: